Selected work
A curated set of pieces, originally published on peptidehackerlab.com. These represent the editorial standards described on the methodology page and the work I'd point a careful reader at first. For my current commentary on the same lean-mass question, see my read on the GRAMS tirzepatide muscle and bone trial.
GLP-1 receptor agonists
Tirzepatide Outperforms Semaglutide on Prediabetes Reversal in SURMOUNT-5 Post Hoc Analysis
Hook on PMID 42002673, the SURMOUNT-5 secondary analysis showing tirzepatide reverses prediabetes to normoglycemia at higher rates than semaglutide over 72 weeks.
Ann Intern Med Review Puts a Number on Lean Mass Loss With Tirzepatide and Semaglutide
What the systematic review at PMID 41996180 actually concludes about how much lean mass GLP-1 therapies cost their users versus caloric restriction alone.
GHRH analogs
Tesamorelin Research Guide
Reference article on the only FDA-approved GHRH analog with a finished-dose indication. The GROW1/GROW2 evidence base, the visceral-fat mechanism, and what's unanswered.
Peptide Receptor Desensitization and Cycling: Research Guide
Receptor downregulation across ipamorelin, hexarelin, CJC-1295, and sermorelin, why protocol design is built around it, and what the controlled data actually demonstrates.